FDA’s Drug Labeling Decisions Complicated By Uncertain Target Audience, Limited Authority
Executive Summary
Do drug labels try to serve too many masters? With no clear agreement on drug labels’ end user and FDA’s incomplete control of label content, the agency and its Pharmaceutical Science Advisory Committee struggle over how to convey drug-drug interaction information in labeling.
You may also be interested in...
FDA’s Label Conversion Project Would Revise Data As Well As Reformat
Solicitation asks for contractor to reformat labels to physician labeling rule format, including updates with new information from literature; generic companies like contractor, while brands say it will be resource-intensive for industry and FDA.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.